{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/analgesia-mild-to-moderate-pain/management/aspirin/","result":{"pageContext":{"chapter":{"id":"4e42679f-766d-53a7-bf28-4ec3703913a8","slug":"aspirin","fullItemName":"Scenario: Aspirin","depth":2,"htmlHeader":"<!-- begin field b4510f66-34c9-40ce-a676-0ee9a1b335b3 --><h2>Scenario: Aspirin</h2><!-- end field b4510f66-34c9-40ce-a676-0ee9a1b335b3 -->","summary":"Covers prescribing information on aspirin, including information on adverse effects, interactions, safety in pregnancy and breastfeeding, and general advice.","htmlStringContent":"<!-- begin item ca1e43bd-07b4-4427-aded-aeea93bbd56f --><!-- begin field 1ad974f4-df4c-4cda-84eb-acd900ad05d3 --><p>From age 16 years onwards.</p><!-- end field 1ad974f4-df4c-4cda-84eb-acd900ad05d3 --><!-- end item ca1e43bd-07b4-4427-aded-aeea93bbd56f -->","topic":{"id":"bb91de96-92a3-5109-9e63-bfa14430451f","topicId":"c277ec09-8e05-40f0-800e-256a40ea6318","topicName":"Analgesia - mild-to-moderate pain","slug":"analgesia-mild-to-moderate-pain","lastRevised":"Last revised in August 2020","chapters":[{"id":"5ad4aa62-330c-58ef-be3d-541eb0757bd1","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"f5da487f-1d70-5390-8b2c-eb8ac55dcca3","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"799ae015-7ff2-5d0f-adc6-2b88d19ac732","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"d1128e99-9465-5c81-aa62-b5dfbd77231a","slug":"changes","fullItemName":"Changes"},{"id":"74a19ac7-0b43-56ee-9957-80e1aee10f72","slug":"update","fullItemName":"Update"}]},{"id":"2ec6ad9e-fe4e-5338-be0a-025956dceeda","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"b5e613c3-899b-5b4e-8648-ff702aef6111","slug":"goals","fullItemName":"Goals"},{"id":"8fb7a002-3c19-5ab7-9ddf-8376dd8f563b","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"12cf7805-8394-59b8-9dc6-25f55b2baece","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"6816edfb-26c1-526d-8e15-0e9c45a99339","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"19cfc3fb-520c-5889-9816-9a767e365a43","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"85fbc6d5-aea7-52dd-8e2b-7792809cf582","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"75f84317-2f35-533b-a07b-8de3c3e62947","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"0728ca52-ba22-539a-b403-09fa11cd8022","slug":"definition","fullItemName":"Definition"},{"id":"732f85cd-41d9-5528-96c3-6f242e3f8736","slug":"types-of-analgesics","fullItemName":"Types of analgesics"},{"id":"4cc4aec7-c1bc-587e-8e30-2bd567709a43","slug":"mode-of-action","fullItemName":"Mode of action"}]},{"id":"3072fb03-9470-5fa4-a035-2669e98df9d8","fullItemName":"Management","slug":"management","subChapters":[{"id":"2d9072b9-4eca-5f7a-9016-80d79ab0bd7d","slug":"choice-of-analgesic","fullItemName":"Scenario: Choice of analgesic"},{"id":"7088bd75-8950-5c20-845e-a5d6297eed85","slug":"paracetamol","fullItemName":"Scenario: Paracetamol"},{"id":"b32885df-ba75-5a6e-9fd1-cb1b6c9ee730","slug":"nsaids","fullItemName":"Scenario: NSAIDs"},{"id":"4e42679f-766d-53a7-bf28-4ec3703913a8","slug":"aspirin","fullItemName":"Scenario: Aspirin"},{"id":"cde4894f-b757-565e-ba2c-44513235cd40","slug":"weak-opioids","fullItemName":"Scenario: Weak opioids"}]},{"id":"d9fe8003-4836-534b-a8e5-d706bd32213c","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"dcff9956-cb3d-54cf-b249-d2c1cdaa2596","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"bce5b7d5-7da6-573e-b8a8-fddc2c7e96b6","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"a15bfc66-55aa-561e-ae5e-8fea7ee56982","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"13a5c6cf-ff3c-5c3d-98fd-5f14e4ee6e2a","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"66abd73d-e881-52a3-8a3a-46e9f9dea2ff","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"73f91468-8f42-546a-86e1-078847155ad0","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"a93d2597-ba76-5709-9989-de6b10c60c42","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"3072fb03-9470-5fa4-a035-2669e98df9d8","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"95bbe8c8-d8e4-5ed0-8453-369da901ad6f","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 4145f355-dba9-4283-aabd-b1c846a8e655 --><h3>What are the contraindications and cautions for aspirin?</h3><!-- end field 4145f355-dba9-4283-aabd-b1c846a8e655 -->","summary":null,"htmlStringContent":"<!-- begin item 162f9cb1-d0ca-41e8-957c-4e347b6ca9de --><!-- begin field 8c2e4c0f-de08-465c-83f9-7a94f7afabd7 --><ul><li><strong>Do not prescribe aspirin</strong> <strong>to</strong>:<ul><li>People with: <ul><li>Nasal polyps associated with asthma — due to a high risk of severe sensitivity reactions.</li><li>Active peptic ulceration or a past history of ulceration or dyspepsia — due to an increased risk of bleeding.</li><li>Haemophilia or other bleeding disorder (including thrombocytopenia) — due to an increased risk of bleeding.</li><li>Severe hepatic impairment — due to the increased risk of gastrointestinal bleeding.</li><li>Severe chronic kidney disease (CKD) stage 4 or estimated glomerular filtration rate (eGFR) of 15–29 – due to the increased risk of deterioration of renal function and GI bleeding.</li><li>Severe cardiac failure.</li></ul></li><li>Children younger than 16 years of age (unless specifically indicated by a specialist, for example for Kawasaki disease) — due to the risk of Reye's syndrome (a very rare but often fatal disease characterized by encephalopathy and fatty degeneration of the liver).</li><li>Women who are in the third trimester of pregnancy or who are breastfeeding — see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/management/aspirin/#pregnancy-breastfeeding\">Pregnancy or breastfeeding</a> for more information.</li></ul></li><li><strong>Prescribe aspirin with caution</strong><strong>:</strong><ul><li>In people with:<ul><li>Anaemia — may be exacerbated by gastrointestinal blood loss.</li><li>Asthma — aspirin may precipitate bronchospasm and asthma attacks in susceptible people. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/asthma/\">Asthma</a> for more information.</li><li>Cardiac failure (or other conditions that predispose to fluid retention).</li><li>Dehydration — may result in deterioration of renal function.</li><li>Uncontrolled blood pressure — due to significant bleeding risk.</li><li>Glucose-6-phosphate dehydrogenase deficiency — rarely aspirin causes haemolytic anaemia.</li><li>Gout — serum urate may be increased.</li><li>Systemic lupus erythematosus and other connective tissue disorders — hepatic and renal function may be impaired in these conditions.</li><li>Thyrotoxicosis — may be exacerbated by large doses of salicylates.</li><li>Mild-to-moderate renal impairment.</li><li>Mild-to-moderate hepatic impairment. </li></ul></li><li>In elderly people — as they are particularly susceptible to adverse effects, especially gastrointestinal bleeding and perforation, which may be fatal. Where prolonged treatment is required, review the person regularly.</li><li>If there is an increased risk of bleeding, for example:<ul><li>During or after operative procedures (even in cases of minor procedures, such as tooth extraction) — temporary discontinuation of treatment may be necessary.</li><li>In those receiving treatment with warfarin or drugs known to increase the risk of gastrointestinaI bleeding, such as other nonsteroidal anti-inflammatory drugs (NSAIDs) or corticosteroids — see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/management/aspirin/#drug-interactions\">Drug interactions</a> for further information.</li></ul></li></ul></li></ul><!-- end field 8c2e4c0f-de08-465c-83f9-7a94f7afabd7 --><!-- end item 162f9cb1-d0ca-41e8-957c-4e347b6ca9de -->","subChapters":[{"id":"0755bc5b-bfa2-5cea-84f3-93ec77f78cbf","slug":"basis-for-recommendation-255","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 71ab860e-5247-4652-9aa5-cba097be60fd --><h4>Basis for recommendation</h4><!-- end field 71ab860e-5247-4652-9aa5-cba097be60fd -->","summary":null,"htmlStringContent":"<!-- begin item 255f9fe8-b897-4e63-9f47-c30c2c88b065 --><!-- begin field 8ca685f6-7753-4de4-831c-6e68a88b0bd8 --><p>These recommendations are largely based on the manufacturer's Summary of Product Characteristics (SPC) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">ABPI, 2020e</a>] and the British National Formulary (BNF) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">Joint Formulary Committee, 2020</a>]. The information on aspirin and the risk of Reye's syndrome in people younger than 16 years of age is also based on the Medicines and Healthcare Products Regulatory Agency (MHRA) publication <em>Aspirin and Reye's in children up to and including 15 years of age</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">CSM, 2002</a>].</p><!-- end field 8ca685f6-7753-4de4-831c-6e68a88b0bd8 --><!-- end item 255f9fe8-b897-4e63-9f47-c30c2c88b065 -->","subChapters":[]}]},{"id":"cb893a43-9c37-5beb-8f5d-c5e3e453bc36","slug":"recommended-doses","fullItemName":"Recommended doses","depth":3,"htmlHeader":"<!-- begin field 03cafd1d-b62e-4940-959c-4286b1d79bd7 --><h3>What dose of aspirin should I prescribe?</h3><!-- end field 03cafd1d-b62e-4940-959c-4286b1d79bd7 -->","summary":null,"htmlStringContent":"<!-- begin item 26cb99c2-5a5f-4207-b8bd-46c8821c39d9 --><!-- begin field 0c311814-1c6d-4e64-9e39-1a7a38f5db56 --><ul><li><strong>The recommended analgesic dose of oral aspirin for mild-to-moderate pain in adults and children older than 16 years of age is:</strong><ul><li>300–900 mg every 4 to 6 hours as required (maximum 4 g in 24 hours).</li></ul></li><li><strong>The recommended oral dose of aspirin for acute migraine is </strong>900 mg for one dose, to be taken as soon as migraine symptoms develop. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/migraine/\">Migraine</a> for more information.</li></ul><!-- end field 0c311814-1c6d-4e64-9e39-1a7a38f5db56 --><!-- end item 26cb99c2-5a5f-4207-b8bd-46c8821c39d9 -->","subChapters":[{"id":"fe864caf-2554-57f2-9961-5f40c5cf31cd","slug":"basis-for-recommendation-004","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field b2a960ef-1a4f-4f70-bb16-bd2e2ec337ee --><h4>Basis for recommendation</h4><!-- end field b2a960ef-1a4f-4f70-bb16-bd2e2ec337ee -->","summary":null,"htmlStringContent":"<!-- begin item 00484866-28f2-44c1-a2ea-a4ed1fe64f04 --><!-- begin field 23c7e614-dc51-4c65-9c93-6a19027254f6 --><p>This recommendation is based on the British National Formulary (BNF) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">Joint Formulary Committee, 2020</a>].</p><!-- end field 23c7e614-dc51-4c65-9c93-6a19027254f6 --><!-- end item 00484866-28f2-44c1-a2ea-a4ed1fe64f04 -->","subChapters":[]}]},{"id":"fd577833-66f9-52cb-92c0-4cb5b7ba9dfe","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 877915f9-37d9-4701-b821-dfe673e94612 --><h3>What are the adverse effects of aspirin?</h3><!-- end field 877915f9-37d9-4701-b821-dfe673e94612 -->","summary":null,"htmlStringContent":"<!-- begin item 40dcb4bc-243c-41bc-a359-acd1a1f8c4ee --><!-- begin field 9ea07f4d-9f33-4379-9187-e2a980896317 --><ul><li><strong>Gastrointestinal (GI) irritation </strong>with slight asymptomatic blood loss is common.</li><li><strong>Bronchospasm and asthma attacks or other hypersensitivity reactions</strong> may occur. Risk factors are existing asthma, hay fever, nasal polyps, or chronic respiratory diseases. </li><li><strong>Other adverse effects include:</strong><ul><li>Uncommon:<ul><li>Dyspnoea, rhinitis, severe cutaneous adverse reactions (SCARs), and skin reactions.</li></ul></li><li>Rare or very rare:<ul><li>Agranulocytosis, aplastic anaemia, erythema nodosum, severe GI bleed, agranulocytosis, haemorrhagic vasculitis, intracranial haemorrhage, menorrhagia, nausea and vomiting, and thrombocytopenia.</li></ul></li><li>Frequency unknown:<ul><li>Fluid retention, GI disorders, headache, hearing loss, hepatic failure, hyperuricaemia, iron deficiency anaemia, renal impairment, sodium retention, tinnitus, and vertigo.</li></ul></li></ul></li></ul><!-- end field 9ea07f4d-9f33-4379-9187-e2a980896317 --><!-- end item 40dcb4bc-243c-41bc-a359-acd1a1f8c4ee -->","subChapters":[{"id":"d362bf6c-82ce-51e8-9f47-2d410bba5bec","slug":"basis-for-recommendation-333","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 5546e18f-aef1-4596-beab-d728ae6aa724 --><h4>Basis for recommendation</h4><!-- end field 5546e18f-aef1-4596-beab-d728ae6aa724 -->","summary":null,"htmlStringContent":"<!-- begin item 33308616-e1cd-449b-94bb-905862da686d --><!-- begin field 2d3090f6-956f-4c3d-8e91-f3abce5df9fb --><p>This information is based on the manufacturer's Summary of Product Characteristics (SPC) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">ABPI, 2020e</a>] and the British National Formulary (BNF) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">Joint Formulary Committee, 2020</a>].</p><!-- end field 2d3090f6-956f-4c3d-8e91-f3abce5df9fb --><!-- end item 33308616-e1cd-449b-94bb-905862da686d -->","subChapters":[]}]},{"id":"7fcace93-d6c8-53c5-be0e-f5083edbb38a","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field c7fcc4f6-b8e1-4644-be9b-a868ec667ae9 --><h3>What are the key drug interactions with aspirin and how should I manage them?</h3><!-- end field c7fcc4f6-b8e1-4644-be9b-a868ec667ae9 -->","summary":null,"htmlStringContent":"<!-- begin item 7fb10e27-9397-4edf-9fba-0df1ed830e4b --><!-- begin field e78075e5-f4cc-40ae-9133-4bef44355686 --><ul><li><strong>Drug interactions with aspirin include:</strong><ul><li>Methotrexate — concurrent use with aspirin enhances haematological toxicity of methotrexate due to the decreased renal clearance of methotrexate.<ul><li>Concurrent use of methotrexate (at doses over 15 mg per week) with aspirin is contraindicated. </li></ul></li><li>Drugs known to increase the risk of gastrointestinal (GI) bleed — risk of bleeding is increased during concurrent treatment with aspirin.<ul><li>Consider switching to a different analgesic (such as paracetamol). If aspirin is indicated, use with caution. Consider gastroprotection (for example with a proton pump inhibitor) during concurrent use.</li><li>Other drugs known to increase the risk of GI bleeding include anticoagulants (for example warfarin), selective serotonin reuptake inhibitors (SSRIs), serotonin-noradrenaline reuptake inhibitors (SNRIs), other nonsteroidal anti-inflammatory drugs (NSAIDs, such as naproxen and ibuprofen), corticosteroids, and clopidogrel.</li></ul></li><li>Diuretics — aspirin (high-dose) increases the risk of acute renal failure when given with diuretics, due to the decreased glomerual filtration via decreased renal prostaglandin synthesis.<ul><li>The manufacturer recommends hydrating the person and monitoring renal function at the start of the treatment.</li></ul></li><li>Antihypertensive drugs — NSAIDs (such as aspirin) may decrease the antihypertensive effects of diuretics and other antihypertensive drugs, and concurrent administration with angiotensin-converting-enzyme inhibitors (such as ramipril) increases the risk of acute renal insufficiency.</li><li>Varicella vaccine — Reye's syndrome has been reported following the use of salicylates during wild-type varicella infection.<ul><li>People who receive the varicella vaccine should avoid use of aspirin for 6 weeks after vaccination.</li></ul></li><li>Nicorandil — aspirin is predicted to increase the risk of GI perforation when given with nicorandil.<ul><li>Manufacturer advises caution.</li></ul></li><li>Omega-3-acid ethyl esters — predicted to increase the risk of bleeding events when given with aspirin.<ul><li>Manufacturer advises use with caution or avoid.</li></ul></li><li>Sulfonylureas — aspirin may increase the hypoglycaemic effect of sulfonylureas.<ul><li>Monitor blood glucose carefully. Dose adjustment may be necessary.</li></ul></li><li>Digoxin and lithium — aspirin may impair the renal excretion of digoxin and lithium, resulting in increased plasma concentrations.<ul><li>Monitor plasma concentrations of digoxin and lithium when initiating and stopping treatment with aspirin. Dose adjustment may be necessary.</li></ul></li></ul></li><li><strong>See the <a data-hyperlink-id=\"91bc0f7b-d72b-417f-93d9-a98c00d870a8\" href=\"http://www.medicines.org.uk/emc\">electronic Medicines Compendium</a> (eMC) or the <a data-hyperlink-id=\"27c10c25-b695-4ce5-b76d-a98c00d87121\" href=\"https://bnf.nice.org.uk/\">British National Formulary</a> (BNF) for a list of all possible drug interactions with aspirin.</strong></li></ul><!-- end field e78075e5-f4cc-40ae-9133-4bef44355686 --><!-- end item 7fb10e27-9397-4edf-9fba-0df1ed830e4b -->","subChapters":[{"id":"fd1b33ee-4aee-5169-95ab-9cdfb716f279","slug":"basis-for-recommendation-4d4","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 5e785f7c-678e-4ec0-b273-faf6519ad57c --><h4>Basis for recommendation</h4><!-- end field 5e785f7c-678e-4ec0-b273-faf6519ad57c -->","summary":null,"htmlStringContent":"<!-- begin item 4d4f3397-db34-4fab-b76a-03259428bb9c --><!-- begin field d7c2aecd-9d67-46c5-bd9c-6e7bd80ff715 --><p>These recommendations are based on the manufacturer's Summary of Product Characteristics (SPC) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">ABPI, 2020e</a>] and the British National Formulary (BNF) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">Joint Formulary Committee, 2020</a>].</p><!-- end field d7c2aecd-9d67-46c5-bd9c-6e7bd80ff715 --><!-- end item 4d4f3397-db34-4fab-b76a-03259428bb9c -->","subChapters":[]}]},{"id":"f9b7c267-cda7-5ee9-9199-325a61dea814","slug":"pregnancy-breastfeeding","fullItemName":"Pregnancy and breastfeeding","depth":3,"htmlHeader":"<!-- begin field aaae0582-c950-4357-8d6f-e22185c23ddb --><h3>Can I prescribe aspirin to a woman who is pregnant or breastfeeding?</h3><!-- end field aaae0582-c950-4357-8d6f-e22185c23ddb -->","summary":null,"htmlStringContent":"<!-- begin item 02559cb6-b770-4f63-a1ed-55d5e782c0d4 --><!-- begin field 124a42f4-524e-42da-8994-fd2ac469f668 --><ul><li><strong>Pregnancy</strong><ul><li>Paracetamol is the analgesic of choice during pregnancy.</li><li>If aspirin is being considered, be aware that analgesic doses of aspirin:<ul><li>Are not known to be harmful when used during the first and second trimesters of pregnancy.</li><li>Should be avoided during the third trimester of pregnancy because:<ul><li>There is an increased risk of haemorrhage due to impaired platelet function.</li><li>There may be delayed onset and increased duration of labour, with increased blood loss.</li><li>High doses (4 g or more) may be related to intrauterine growth restriction, teratogenic effects, closure of fetal ductus arteriosus in utero, and possibly persistent pulmonary hypertension of the newborn, and kernicterus may develop in babies who are jaundiced. </li></ul></li></ul></li></ul></li><li><strong>Breastfeeding</strong><ul><li>Paracetamol is the analgesic of choice during breastfeeding. </li><li>Do not prescribe analgesic doses of aspirin to women who are breastfeeding due to a possible risk of Reye's syndrome (a very rare but often fatal disease characterized by encephalopathy and fatty degeneration of the liver) in the baby.</li></ul></li></ul><!-- end field 124a42f4-524e-42da-8994-fd2ac469f668 --><!-- end item 02559cb6-b770-4f63-a1ed-55d5e782c0d4 -->","subChapters":[{"id":"8d521407-5c32-5368-88e9-1b7c0c25e881","slug":"basis-for-recommendation-138","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 582cf990-cbdb-4539-a277-dfe1ad028e15 --><h4>Basis for recommendation</h4><!-- end field 582cf990-cbdb-4539-a277-dfe1ad028e15 -->","summary":null,"htmlStringContent":"<!-- begin item 1380e2a7-2cc1-4e5f-8991-fd39e54046e3 --><!-- begin field 94441d2f-a841-4440-8ef7-897fe311fb81 --><h5>Pregnancy</h5><ul><li>There is no evidence that taking low doses of aspirin in pregnancy will harm the baby, and for some women it may be recommended [<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">BUMPS, 2020</a>]:<ul><li>The National Institute for Health and Care Excellence (NICE) recommends low-dose aspirin (75–150 mg once daily from 12 weeks) for pregnant women at high risk of pre-eclampsia. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/hypertension-in-pregnancy/\">Hypertension in pregnancy</a> for more information.</li><li>Low-dose aspirin is sometimes used from conception for women undergoing fertility treatment and those with a history of recurrent miscarriage or conditions such as antiphospholipid syndrome, as some studies have suggested an improvement in live birth rates [<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">UKTIS, 2019</a>].</li></ul></li><li>The UK Teratology Information Service (UKTIS) states that [<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">UKTIS, 2019</a>]:<ul><li>Increased risks of gastroschisis, cleft lip and palate, and neural tube defects have been reported following maternal use of aspirin during pregnancy (mainly at analgesic doses); however, data are conflicting and may also be confounded, and a causal association with aspirin has not been proven. Data relating to risk of cardiac malformations are reassuring.</li><li>Regular use of analgesic doses of aspirin in the third trimester should be avoided if possible. In circumstances where the maternal clinical condition requires treatment with analgesic doses of aspirin during the third trimester, fetal monitoring for oligohydramnios and ductus arteriosus patency is recommended. Exposure to analgesic doses of aspirin prior to the third trimester would not be considered an indication for any additional fetal monitoring.</li><li>No data are available on pregnancy outcomes following aspirin use at analgesic doses, and data on neurodevelopmental outcomes following in utero aspirin exposure at any dose are too limited to facilitate an evidence-based assessment of risk.</li><li>Chronic exposure to analgesic doses of aspirin (more than 300 mg per day from 30 weeks of pregnancy) may be associated with neonatal bleeding complications and premature closure of the ductus arteriosus, resulting in pulmonary vasculature abnormalities and persistent pulmonary hypertension of the newborn. These effects have not been reported with low-dose aspirin use.</li></ul></li></ul><h5>Breastfeeding</h5><ul><li>The UK Medicines Information (UKMi) states that [<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">UKMi, 2018</a>]:<ul><li>Several case reports have described serious adverse effects in infants exposed to aspirin via breast milk in mothers taking analgesic or anti-inflammatory doses, including thrombocytopenia, fever, anorexia, and petechiae, and haemolysis in a G6PD deficient infant. A case report reported metabolic acidosis in an infant; however, it could not rule out direct administration of aspirin to the infant.</li><li>Aspirin has been definitively associated with Reye’s syndrome when administered to children with fever. A definitive dose-related relationship between aspirin and Reye’s syndrome has not been established, and it is unknown whether the small amounts present in breast milk following an antiplatelet dose would be clinically significant. To minimize the risk of developing Reye’s syndrome, breastfeeding should be withheld if the infant develops a fever. In some cases it may also be clinically appropriate to withhold the aspirin for short periods in order to avoid disrupting breastfeeding.</li></ul></li><li>The manufacturer's Summary of Product Characteristics (SPC) states that low quantities of salicylates and of their metabolites are excreted into the breast milk but adverse effects for the infant have not been reported up to now. It recommends that breastfeeding should be discontinued during long-term use and/or administration of higher doses of aspirin [<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">ABPI, 2020e</a>].</li><li>Both the SPC and the British National Formulary (BNF) state that aspirin should be avoided during breastfeeding because of the possible risk of Reye’s syndrome. In addition, regular use of high doses of aspirin could impair platelet function and produce hypoprothrombinaemia in infants if neonatal vitamin K stores are low [<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">ABPI, 2020e</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">Joint Formulary Committee, 2020</a>].</li></ul><!-- end field 94441d2f-a841-4440-8ef7-897fe311fb81 --><!-- end item 1380e2a7-2cc1-4e5f-8991-fd39e54046e3 -->","subChapters":[]}]},{"id":"c0bcb63e-5982-54f7-b240-e39592d25810","slug":"information-advice","fullItemName":"Information and advice","depth":3,"htmlHeader":"<!-- begin field e6f9b9db-b9b4-4193-a68c-d76b65c5b7c2 --><h3>What information and advice should I give to a person receiving aspirin?</h3><!-- end field e6f9b9db-b9b4-4193-a68c-d76b65c5b7c2 -->","summary":null,"htmlStringContent":"<!-- begin item d05f6a0d-486d-46d6-9ed3-e3bd2c0e61a8 --><!-- begin field 07a5db9b-680e-44d3-97ce-951eb9c2c3c8 --><ul><li><strong>Advise the person to:</strong><ul><li>Take aspirin with or after food (to reduce the risk of gastrointestinal <a class=\"topic-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/management/aspirin/#adverse-effects\">adverse effects</a>).</li><li>Stop aspirin and seek medical advice if they experience bronchospasm or dyspepsia.</li><li>Seek advice from a healthcare professional (such as a pharmacist) before buying over-the-counter (OTC) medicines. These might contain ingredients (for example ibuprofen) that can increase the risk of adverse effects from aspirin.</li></ul></li><li><strong>Provide written information on aspirin and pain management.</strong><ul><li>The British Pain Society leaflet <a data-hyperlink-id=\"117e9632-6c21-4c3b-906d-ac0a01370395\" href=\"https://www.britishpainsociety.org/static/uploads/resources/files/patient_pub_otc.pdf\">Managing your pain effectively using “Over the Counter” (OTC) Medicines</a> discusses the short- and long-term use of OTC analgesics and their associated adverse effects.</li><li>The NHS website (<a data-hyperlink-id=\"ce42e858-f50b-454c-9ef2-ac0a013703a4\" href=\"https://www.nhs.uk/\">www.nhs.uk</a>) has information on <a data-hyperlink-id=\"60b56535-8791-4098-a0ab-ac12014ad56b\" href=\"https://www.nhs.uk/medicines/aspirin-for-pain-relief/\">Aspirin for pain relief</a>.</li></ul></li></ul><!-- end field 07a5db9b-680e-44d3-97ce-951eb9c2c3c8 --><!-- end item d05f6a0d-486d-46d6-9ed3-e3bd2c0e61a8 -->","subChapters":[{"id":"6585d094-6aac-5c3a-bdae-da53f82b46a2","slug":"basis-for-recommendation-2a2","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 5127f9a5-e65c-477c-b393-291117404025 --><h4>Basis for recommendation</h4><!-- end field 5127f9a5-e65c-477c-b393-291117404025 -->","summary":null,"htmlStringContent":"<!-- begin item 2a249503-be63-486f-9384-4214c401e653 --><!-- begin field 5f3ffb7c-80ea-48bf-b9e4-099255fa32f7 --><p>These recommendations are based on what CKS considers to be good clinical practice.</p><!-- end field 5f3ffb7c-80ea-48bf-b9e4-099255fa32f7 --><!-- end item 2a249503-be63-486f-9384-4214c401e653 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}